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evaluated in reversible and time-dependent cytochrome P450 (CYP) 3A inhibition assays in rat liver
microsomes using testosterone as probe substrate. Both compounds were found to be weak
reversible inhibitors and moderate mechanism-based inhibitors of rat CYP3A. For reversible
inhibition on rat CYP3A, the Ki values of competitive inhibition model were 12.1071.75 and
13.9471.31 mM, respectively. For time-dependent inhibition, the inactivation constants (Kl) were
31.93712.64 and 32.91715.58 mM, respectively, and the maximum inactivation rates (kinact) were
0.0349770.0069 and 0.0725970.0172 min1 respectively. These ﬁndings would provide useful
in vitro information for future in vivo DDI studies on TM208 or TM209.
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Dithiocarbamate derivatives are a common class of organic
molecules with various valuable biological effects. They are well-
known to be used as fungicides1. Dithiocarbamate has antibiotic
and anti-inﬂammatory properties2, promote nitrogen monoxi-
dum elimination from the body, as well as chelate heavy metals
in the body3,4. In addition, dithiocarbamate is used to prevent
or treat cancer. A series of new dithiocarbamate derivatives has
been synthesized, including TM209 and TM208 (Fig. 1)5–7.
Previous studies showed that TM208 displayed anti-cancer
activities in vitro and in vivo with low toxicity8,9 and TM209
was found to be more potent in vitro than TM2085. TM208 and
its metabolites were identiﬁed in rat plasma, bile and feces,
and only phase I metabolites were discovered10–14. In rat liver
microsomes (RLMs), TM208 was mainly metabolized by
CYP2D and CYP2B, and CYP1A inhibitor had a modest
inhibitory effect on TM208 metabolism15. However, there are
no studies on potential DDI screening of the two compounds.
Clinical DDIs largely result from the inhibition or induction
of drug metabolizing enzymes, particularly CYPs16. Among
the drug metabolizing CYP subfamilies, the CYP3A subfamily
is considered to have the greatest overall impact on human
drug metabolism. The CYP3A subfamily comprises the most
abundantly expressed CYPs in human liver (30% of total
hepatic CYP protein) and small intestine. Moreover, its
members possess metabolic activity toward more than 50%
of all known therapeutic drugs, as well as many endogenous
compounds17. Prone to inhibition by many xenobiotics, CYP3A
should be screened in early drug development of potential DDI
caused by inhibition. CYP3A inhibition may be reversible and/or
irreversible. Irreversible inhibition, also referred to as mechan-
ism-based inhibition, is characterized by time-dependent and
inhibitor concentration-dependent loss of enzyme activity18. A
mechanism-based inhibitor inhibits the enzyme through irrever-
sibly or quasi-irreversibly binding to the enzyme; thus, the
enzyme activity does not return immediately upon elimination
of the inhibitor from plasma or tissue19. Interestingly, many
clinically signiﬁcant CYP3A4 inhibitors have been shown to
possess, to varying extents, both reversible and irreversible
inhibitory effects on CYP3A20,21. As a result, administrations
such as FDA, SFDA and pharmaceutical industries have issued
related guidance and perspectives on in vitro and in vivo DDI
screen conduction22–24.
Since anti-cancer agents are often used concomitantly with
other drugs which may be CYP3A substrates and have narrow
therapeutic windows, it is necessary to screen potential
reversible and irreversible CYP3A inhibition in early drug
research and development process. The aim of this study was
to evaluate the effect of TM208 and TM209 on CYP3A
activity in RLM to predict the potential DDI that may occurFigure 1 The chemical structures of TM208 and TM209.in drug combination based on CYP3A reversible or mechan-
ism-based inhibition.2. Materials and methods
2.1. Animals and treatments
Normal male Sprague-Dawley rats weighing 200–250 g were
purchased from the Department of Laboratory Animal
Science at the Peking University Health Science Center. The
animals were housed and acclimatized in a temperature
(22 1C) and light-controlled (12 h/12 h light/dark) animal care
unit for 10 days before experimentation. The rats were
anesthetized with 60 mg/kg pentobarbital sodium and sacri-
ﬁced, then approximately 4 g of liver was rapidly excised for
the preparation of liver microsomes16,25,26. Liver microsomes
of 9 rats were pooled and stored in 80 1C. The total protein
concentration of rat liver microsome was determined by BCA
protein assay kit.
2.2. Chemicals and reagents
TM208 and TM209 were provided by Professor Runtao Li
(Peking University). Testosterone and prednisonlone were
obtained from J&K (China). NADPH was obtained from
Roche (Switzerland). BCA protein assay kit was purchased
from Beyotime (China). HPLC grade acetonitrile and metha-
nol were purchased from Promptar Company Ltd. (Canada).
DMSO was obtained from Sigma-Aldrich (China). Ethyl
acetate and other reagents were purchased from Sinopharm
Chemical Reagent Co., Ltd (China). Water was obtained from
Watsons (China).
2.3. Instrumentation
T10 homogenizer (IKA, Germany); TGL-16G centrifuge
(Anke, China); CHA-S air bath shaker (Ronghua, China);
MD 200 sample concentrator (Chiheng Technology Co., Ltd.,
China); 1100 HPLC system equipped with G1311A Quat
pump, G1316A column compartment and G1365B MWD
UV detector (Agilent, US).
2.4. Metabolism kinetics of testosterone
CYP3A activity in RLM was determined as 6b-hydroxytes-
tosterone formation rate. All the samples were prepared in
triplicate. In all cases of incubation, no more than 10% of the
substrate was consumed. TM208 and TM209 were dissolved in
DMSO. The ﬁnal concentration of DMSO in the incubation
was less than 0.1% (v/v). Testostrone was dissolved in
acetonitrile and the ﬁnal volume of solvents in the incubation
was less than 1% (v/v).
Incubation mixtures, 200 mL in volume, contained Tris–HCl
buffer (50 mM Tris, 150 mM KCl and 10 mMMgCl2, pH 7.4),
1.25 mM NADPH, 0.5 mg protein/mL RLM and testosterone
(ﬁnal concentration at 25, 50, 75, 100, 150, 200, 250 and
300 mM). Mixtures of testosterone and RLM were pre-incu-
bated at 37 1C for 5 min in shaking air bath and NADPH was
pre-incubated separately for 5 min. Reactions were initiated
with the addition of NADPH. After incubation at 37 1C for
Figure 2 The metabolism kinetics of testosterone. The circles were
the mean value of observed data with bars representing standard
error (n¼3), the curve was Michaelis–Menten ﬁtting of the data.
In Vitro screening of inhibition of CYP3A by TM208 and TM209 in rat liver 1835 min, the reactions were quenched by adding 100 mL cold
acetonitrile containing 10 mg/mL prednisonlone as internal stan-
dard and vortexed for 30 s. The samples were extracted by 2 mL
ethyl acetate. After centrifugation at 3000 rpm for 10 min, the
organic layer was transferred to another tube and evaporated to
dryness at 50 1C under a stream of nitrogen. The residue was
reconstituted in 100 mL methanol for HPLC assay.
2.5. Reversible inhibition incubation
Incubation mixtures, 200 mL in volume, contained Tris–HCl
buffer, 1.25 mM NADPH, 0.5 mg protein/mL RLM, inhibi-
tors (TM208 or TM209 at 0, 0.5, 1, 2.5, 5, 10, 25 and 50 mM)
and testosterone (75 mM for IC50 determination; 25, 50, 75,
100, 150 and 250 mM for Ki determination). Mixtures of
testosterone, inhibitor and RLM were pre-incubated at 37 1C
for 5 min in shaking air bath and NADPH was pre-incubated
separately for 5 min. Reactions were initiated with the addition
of NADPH and the incubation lasted for 5 min at 37 1C. The
sample preparation procedure was described as above.
2.6. Time-dependent inhibition incubation
TDI studies were conducted under the 10-time dilution two-
step incubations21,27,28. For IC50 shift test, pre-incubation
mixture contained 2 mg protein/mL RLM, 1.25 mM NADPH
and inhibitors (ﬁnal concentration at 0, 0.5, 1, 2.5, 5, 10 and
25 mM). After 30 min’s pre-incubation with or without
NADPH, 20 mL of the mixture were added to 180 mL mixture
composed of 75 mM28 testosterone and 1.25 mM NADPH to
initiate subsequent incubation for activity assay. The incuba-
tion time was 5 min for the subsequent incubation for CYP
activity assay.
For KI and kinact determination, the pre-incubation time
was 0, 5, 10, 20 and 30 min. The concentration of testosterone
in CYP activity assay was 200 mM28.
2.7. HPLC analysis
The concentration of 6b-Hydroxytestosterone, the product of
testosterone metabolized by CYP 3A in RLMs, was deter-
mined according to the method described by Chovan29, Qiu30
and Li31 with modiﬁcation. In brief, a reversed-phase column
(C18, 250 mm 4.6 mm, 5 mm, Phenomenex Luna, USA)
connected to a guard column (10 mm 4.6 mm C18 cartridge,
5 mm, Watch, USA) was used to separate testosterone and its
metabolites. The column temperature was set at 30 1C. The
mobile phase consisted of water (A) and acetonitrile (B). The
gradient started from 27.5% B for 16 min, then from 27.5% B
to 45% B in 0.5 min, maintained for 11 min, then returned to
27.5%B in 0.5 min followed by 5 min equilibration. The ﬂow
rate was 1 mL/min during the whole chromatographic run
time of 33 min. An aliquot of 50 mL of the extracted sample
was injected into the HPLC system for analysis.
2.8. Data analysis
The formation of a metabolite (6b-hydroxytestosterone) from
testosterone metabolized by CYP 3A in RLM was illustrated
using Michaelis–Menten equation. IC50 values were calculated
from the hydroxylation rate versus inhibitor concentrationplots using following equation:
R¼Rmax=ð1þ ðI=IC50ÞÞ ð1Þ
where R is the 6b-hydroxylation rate, Rmax is the maximum
6b-hydroxylation rate, IC50 is the concentration of test
compound when half of the enzyme activity inhibited and I
is the initial concentration of inhibitor (TM208 or TM209).
To get reversible inhibition constant Ki, the rates of 6b-
hydroxytestosterone formation from testosterone in the pre-
sence of the test inhibitors were compared with those in the
absence of the test inhibitors, which were replaced by vehicle.
Data obtained from investigations of enzyme inhibition were
ﬁt to different models (competitive, non-competitive, and
uncompetitive) using the GraphPad Prizm software.
For TDI, the observed rates of CYP3A inactivation (kobs)
at different inhibitor concentrations were calculated from the
negative slopes of the lines using linear regression analysis of
the natural logarithm of the remaining activity as a function of
time. Then the inhibitor concentration that supports half the
maximal rate of inactivation (Kl) and maximal rate of enzyme
inactivation (kinact) values were calculated based on the
following equation:
kobs ¼ kinact  I=ðKI þ IÞ ð2Þ
where I is the initial concentration of TM208 or TM209, Kl is
the concentration of inhibitor giving half-maximal enzyme
inactivation rate and kinact is the maximal rate of enzyme
inactivation.
Parameters including IC50, Ki, KI and kinact were calculated
using GraphPad Prizm 5.02 (U.S.) by non-linear regression.3. Results and discussion
3.1. Metabolism kinetics of testosterone
The 6b-hydroxylation activity of testosterone followed the
Michaelis–Menten kinetics with Vmax of 27507125.9 pmol/
(min.mg protein) and Km of 74.4079.73 mM (Fig. 2). Our result
of Km is consistent with those of previous studies both on
HLM23,32 and on RLM29. Regarding the incubation condition
optimization, incubation time was investigated in the ﬁrst place to
ensure the later assay within linear metabolism range. Within the
ﬁrst 10 min, the CYP3A metabolic activity of RLM displayed
Miaoran Ning et al.184linear relationship with incubation time (data not shown). Thus,
the ﬁnal incubation time was selected for 5 min. In addition to
incubation time, the concentration of microsome was also
evaluated and ﬁnally set at 0.5 mg protein/mL. According to
previous studies22,28 and FDA guidance23, less than 1 mg protein/
mL would prevent unspeciﬁc binding to ensure data reliability.3.2. Reversible inhibition incubation
When co-incubated with the substrates, TM208 and TM209
were found to be weak inhibitors with similar IC50 values of
20.1872.28 and 15.0272.57 mM, respectively (Fig. 3). In theory,
the degree of DDI (R), expressed as fold of change in AUC, can
be estimated by the following equation: R¼1þ [I]/Ki, where [I] is
the concentration of inhibitor exposed to the active site of the
enzyme and Ki is the inhibition constant
23. Since Ki values fall
between IC50/2 (competitive inhibitors) and IC50 (non-competitive
inhibitors), IC50 values therefore can be a good indication of the
inhibition potency of a potential new drug substance and allow
comparison with other candidate molecules21. The ﬁnal concen-
tration of testosterone for IC50 assay was 75 mM, the RLM
concentration was 0.5 mg protein/mL and the incubation time
was 5 min. This is because the accuracy of IC50 determination is
impacted by a combination of enzyme concentration, substrate,
substrate concentration and incubation time. To ensure theFigure 3 The IC50 of TM208 and TM209. (A) IC50 of reversible inhi
mean value of observed data with bars representing standard error
reversible inhibition by TM209 to CYP3A.
Figure 4 The Ki determination of TM208 and TM209 on inhibition
and TM209 inhibitory data were best ﬁtted to competitive inhibition
RLMs plotted by 6b-hydroxytestosterone formation rate versus initia
on CYP3A.accuracy of the assay, the choice of substrate concentration
should allow no more than 10% depletion and be sensitive to the
presence of the inhibitory compound, which is ideally at Km
concentration when the IC50 is more closely related to its Ki. The
incubation time should allow sufﬁcient metabolite formation to
quantify even when 95% enzyme activity inhibited and within
linear metabolism range at the same time21.
However, for a thorough assessment in vitro to predict DDI
effects in vivo, Ki values are required
23,24. For Ki determina-
tion, different models including competitive, uncompetitive,
non-competitive and mixed-model were compared for best
description of the data. Competitive model was selected for
ﬁnal Ki constant determination according to apparent Vmax
and Km shift
21 and goodness of ﬁtting. Ki of TM208 and
TM209 were 12.1071.75 and 13.9471.31 mM, respectively,
and the goodness of ﬁtting is shown in Fig. 4. Recommended
by FDA23, the ratio of [I]/Ki greater than 0.1 suggested
possible DDI, and it should be evaluated in vivo. This means
that if the in vivo concentrations of TM208 and TM209 under
effective dose are greater than 1.2 and 1.4 mM, respectively,
in vivo DDI studies would be recommended for safety
consideration. Ki experiments typically use a matrix of sub-
strate and inhibitor concentrations spanning a range of at least
0.5 to 5 folds of expected Ki (inhibitor) and Km (substrate)
concentrations24. However, limited by TM208 and TM209
solubility, the maximum concentration for inhibitory assaybition by TM208 to CYP3A activity in RLM, the circles were the
(n¼3), the curve non-linear regression of the data. (B) IC50 of
of 6b-hydroxylation by CYP3A in RLMs (n¼3). Both of TM208
model. (A) reversible inhibition of TM208 on CYP3A activity in
l testosterone concentration. (B) Reversible inhibition of TM209
In Vitro screening of inhibition of CYP3A by TM208 and TM209 in rat liver 185was 50 mM and 25 mM, about 4-fold and 2-fold of expected Ki,
respectively. Since the concentration ranges have cover the Km
of substrate and Ki of the test inhibitors, the experimental
design was acceptable23.3.3. Time-dependent inhibition incubation
The inhibitory effect of TM208 and TM209 on RLM
testosterone 6b-hydroxylation activity was time dependent.
Upon pre-incubation for 30 min in the presence of NADPH,
the value of IC50 shifted from 9.57 to 4.74 mM and 18.18 to
2.17 mM respectively when testosterone 6b-hydroxylase activ-
ity was measured (Fig. 5). IC50 shift experiment was regarded
as the ﬁrst step of TDI assessment. Inhibition curve shifted to
lower IC50 value for a test inhibitor with or without inhibitor
pre-incubation makes a straightforward indication of TDIFigure 6 Pre-incubation time and TM208 or TM209 concentra
6b-hydroxylation activity in rat liver microsomes (n¼3). (A) plo
concentrations in RLMs; the slope of each linear regression line is
incubation in RLM; kinact and KI were estimated by non-linear regres
TM209 concentrations in RLMs. (D) plots of Kobs versus TM208 con
Figure 5 The IC50 shift after pre-incubation for 30 min with TM208
TM208 inhibition on CYP3A in RLMs after pre-incubation for 30 min
RLMs after pre-incubation for 30 min with or without NADPH.effects21,28,33. In addition, excellent correlation between shifted
IC50 and kinact/Kl, an established measure of inactivator
efﬁciency, was observed28, making the approach more rational
for TDI screen.
Regarding the IC50 shifts detected, further studies were
conducted to determine kinact and KI of TM208 and TM209.
The kinetics of rat CYP3A inactivation was described by kinact
of 0.03497 and 0.07259/min, KI of 31.93 and 32.91 mM
respectively for TM208 and TM209 (Fig. 6). The summary
of all TM208, TM209 inhibitory data are listed in Table 1.
The assays of TDI in our research were 10-time dilution two-
step incubations. The 10-time dilution from pre-incubation to
subsequent incubation of CYP activity assay, which dilute both
microsomal concentration and test compound concentration could
minimum the impact of reversible inhibition21,27,28. On the other
hand, diluted concentration of microsome would decrease the
formation of 6b-hydroxytestosterone. Since the LLOQ of thetion-dependent inactivation of CYP3A-catalyzed testosterone
ts of ln(%activity remained) versus time at different TM208
–Kobs. (B) plots of Kobs versus TM208 concentrations at pre-
sion. (C) plots of ln(%activity remained) versus time at different
centrations at pre-incubation in RLM.
or TM209 with or without NADPH (n¼3). (A) the IC50 ﬁtting of
with or without NADPH. (B) The result of TM209 on CYP3A in
Table 1 Reversible and time-dependent inhibition of CYP3A activity by TM208 and TM209 in rat liver microsomes (RLMs)
(n¼3).
Type of inhibition Result TM208 TM209
Reversible inhibition IC50 (mM)
b 20.1872.28 15.0272.57
Ki (mM)
b 12.1071.75 13.9471.31
Time-dependent inhibition IC50 with/without NADPH after
pre-incubation for 30 min (mM)b
9.5771.31/4.7470.78 18.1872.94/2.1770.29
IC50 shift (%)
a 50 88
kinact (/min)
b 0.0349770.00688 0.0725970.01727
KI (mM)
b 31.93712.64 32.91715.58
aIC50 shift¼(IC50 without NADPHIC50 with NADPH)/IC50 without NADPH 100%, calculated from mean values of IC50 with or without
NADPH after a pre-incubation for 30 min.
bData are expressed as mean7SD.
Miaoran Ning et al.186HPLC method used was 0.1 mg/mL and the linear range of the
method was from 0.1 to 10 mg/mL, quantiﬁable formation of
6b-hydroxytestosterone should be no less than 0.1 mg/mL. As a
result, the protein concentration in pre-incubation step had to be
2 mg/mL to ensure sufﬁcient metabolite formation in subsequent
incubation. In spite that protein concentrations of microsome used
is usually less than 1 mg/mL to reduce unspeciﬁc binding of
compounds according FDA relative guidance23, concentration
under 2 mg/mL was acceptable22,28.
Our results indicated TM208 and TM208 had comparable
reversible inhibitory potency to rat CYP3A. However, the
results of comparable KI, concentration of inhibitor giving
half-maximal enzyme inactivation rate, and the increased
kinact, maximal rate of enzyme inactivation, indicated that
TM209 was more potent regarding CYP3A inactivation than
TM208. It is possible that increase in electrophiles because of
different substituent on the 4-N atom was responsible for the
increase potency in TDI of CYP3A by TM209 and TM208.
The pharmacokinetic proﬁle of TM208 was simulated to
predict the in vivo DDI between TM208 and CYP3A substrate.
The hypothesis of simulation were that the pharmacokinetics
(PK) of TM208 was dose independent within the range of
simulation and that the equivalent dose of rat could be extra-
polated by that of nude mouse according to the relationship
between body surface area and dose8. The PK parameters were
calculated using rat PK data in low dose obtained from our
previous studies34, and one compartment model was used. The
doses selected for simulation, 70 and 140 mg/kg day, was extra-
polated from the doses to nude mice xenografted with tumors8.
The Cmax of TM208 after 70 and 140 mg/kg day were 4.36 and
8.72 mM, respectively. According to the in vivo prediction
model of DDI caused by TDI, AUCi/AUCc¼1/{fm  fm,CYP/
[1þ(kinact/KI)  (I/ke)]þ[1fm  fm,CYP]}22,23,36,37, the AUC of
CYP3A substrate would increase no more than 1.37 and 1.75
folds respectively, when fm and fm, CYP, the fraction of metabo-
lism, changed from 0 to 1; ke, ﬁrst-order rate of rat CYP3A
degradation, was 0.0128/min35, and I were Cmax of TM208 after
dose of 70 and 140 mg/kg day. Because of lacking PK proﬁle of
TM209, AUC fold change after co-administration of chronic
doses of TM209 could not be predicted yet. If similar Cmax
reached, the AUC would increase 1.75 and 2.50 folds at most.
Since the anti-cancer activities of TM209 was better than TM208
because of their differences in molecular polarity5, a balance
among efﬁcacy, side effects and toxicity should be weighed in
later on development and lead compound optimization.In addition to CYP3A inhibitory assay, inhibition potency
of other major CYP isoforms of drug metabolizing enzymes
should be screened to predict potential DDIs thoroughly. IC50 of
reversible inhibition of CYP1A, CYP2C9, CYP2C19 and
CYP2D6 in RLMs for TM208 and TM209 was under investiga-
tion using LC-MS/MS assay of probe metabolite formation.
TM208 seemed to be more potent as inhibitors to CYP2C9 and
TM209 was prone to inhibit CYP2C9, CYP2C19 and CYP2D6.
Admittedly, there are inter-species differences in human CYP
and rat CYP29,37. Validation of these inhibitions in human liver
microsomes or human recombinant CYPs would be preferable.
As a result, further studies on potential DDIs based on CYP
inhibition by TM208 and TM209 should be conducted.
4. Conclusions
We have demonstrated for the ﬁrst time reversible and time-
dependent inhibition of TM208 and TM209 on rat CYP3A. Both
compounds were shown to be weak reversible inhibitors23 to rat
CYP3A in in vitro inhibitory assay with similar inhibition con-
stants. In addition, studies of time-dependent inhibition of the
compounds showed that they had moderate potency21 to inacti-
vate CYP3A activity in a time-dependent manner. After all,
further preclinical and clinical drug-interaction studies are needed
to evaluate the relevance of TM208 and TM209 as reversible and
especially mechanism-based inhibitors of CYP3A in human.
When validated by later studies, caution should be taken when
these compounds are chronically dosed with a CYP3A substrate,
especially those with a narrow therapeutic window.
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